ELITE PHARMACEUTICALS INC /NV/ (ELTP) Form 10-Q — Aug 13, 2026
Elite Pharmaceuticals reported quarterly revenue of $32.4 million for the three months ended June 30, 2026, down 20% from $40.2 million a year earlier, as generic competition and lower net prices on its Lisdexamfetamine line compressed gross margin to 42% from 68%. The company swung to net income of $5.9 million ($0.01 per share) from a $5.9 million loss in the prior-year quarter, largely because last year's $22.1 million non-cash warrant fair-value charge did not recur, and it generated $10.1 million in operating cash flow while working capital fell $10.7 million.
Key figures
- Eps
- 0.01
- Revenue
- 32355283
- Net Income
- 5910565
- Revenue Yoy
- -20%
- Shares Outstanding
- 1077136442
- Njeda Bonds
- $4,155,000 at 6.5%, Series A maturing September 1, 2030
- Gross Profit
- 13507545
- Restricted Cash
- 475441
- Working Capital
- 84046088
- Ewb Mortgage Loan
- $2.55 million at 4.75% fixed for first five years
- Operating Income
- 7529281
- Prior Year Revenue
- 40211097
- Total Liabilities
- 34843076
- Warrant Liability
- 17249339
- Gross Margin Current
- 42%
- Shareholders Equity
- 104826056
- Warrants Outstanding
- 79008661
- Gross Margin Prior Year
- 68%
- Working Capital Change
- -$10.7 million QoQ
- Customer Concentration
- Two customers = 73% of quarterly revenue; two customers = 76% of accounts receivable
- Diluted Weighted Shares
- 1128661497
- Supplier Concentration
- Three suppliers = 78% of raw material purchases
- Cost Of Manufacturing Change
- +45% to $18,847,738
- Share Fair Value June30 2026
- 0.3651
- Warrant Weighted Exercise Price
- 0.1521
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.